CRISPR Therapeutics
CRSP
479 hedge funds and large institutions have $4.01B invested in CRISPR Therapeutics in 2025 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 149 increasing their positions, 128 reducing their positions, and 53 closing their positions.
81% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 53
35% more call options, than puts
Call options by funds: $233M | Put options by funds: $172M
16% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 128
9% more funds holding
Funds holding: 440 → 479 (+39)
0.81% more ownership
Funds ownership: 79.43% → 80.24% (+0.81%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
14% less capital invested
Capital invested by funds: $4.68B → $4.01B (-$671M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$58M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$44M |
| 3 |
Squarepoint
New York
|
+$34.8M |
| 4 |
BlackRock
New York
|
+$27.4M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$43.8M |
| 2 |
Two Sigma Investments
New York
|
-$34.4M |
| 3 |
Two Sigma Advisers
New York
|
-$24.6M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$18M |
| 5 |
State Street
Boston,
Massachusetts
|
-$15.2M |
CRSP Hedge Fund Activity: Q4 2025 in Review
479 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2025, worth a combined $4.01B — down 14% from $4.68B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new CRSP positions and 53 closed out — a net gain of 43 holders — while 149 added to existing stakes and 128 trimmed.
The largest buyer was Orbis Allan Gray, adding an estimated $58M. The largest seller was Morgan Stanley, cutting an estimated $43.8M.
- 479 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2025, up from 440 in Q3 2025.
- Funds reported $4.01B of CRISPR Therapeutics stock for Q4 2025, down 14% quarter-over-quarter.
- 96 funds opened new CRISPR Therapeutics positions in Q4 2025 and 53 closed out, a net change of +43 holders.
- The largest CRISPR Therapeutics buyer in Q4 2025 was Orbis Allan Gray, an estimated $58M added.
- The largest CRISPR Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $43.8M sold.
Based on aggregated 13F filings for Q4 2025.